GDRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GoodRx Holdings Inc (GDRX) is not a strong buy at the moment. The stock is facing structural headwinds, declining financial performance, and bearish technical indicators. While there is some growth potential in its Pharma Direct unit, the near-term outlook is pressured. For a beginner investor with a long-term focus, this stock does not currently present a compelling entry point.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 33.992, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 2.027, but there is no clear upward momentum.
The Pharma Direct unit shows potential for growth, as noted by analysts.
Hedge funds are significantly selling the stock, with a 1160% increase in selling activity. Analysts have lowered price targets across the board, citing structural headwinds and reduced take rates in the prescription business. Financial performance is declining, with revenue and net income dropping YoY. No recent news or congress trading data to suggest positive sentiment.
In Q4 2025, revenue dropped by -1.91% YoY to $194.8M, net income fell by -19.51% YoY to $5.43M, and gross margin declined by -6.04% YoY to 79.15%. EPS remained flat at 0.02.
Analysts have significantly lowered their price targets, with most targets now around $2-$3. The ratings are mixed, with some maintaining Buy ratings but others downgrading to Neutral. Near-term growth and margins are expected to remain under pressure.
